Norman R. Hames
Known title: See RemarksCIK: 0000929967
Associated companies
Transaction History
| RDNT | ▲ Buy | Grant | 22,045 | $0 | 3/3/2026 | View on chart |
| RDNT | ▲ Buy | Grant | 3,100 | $0 | 3/3/2026 | View on chart |
| RDNT | ▼ Sell | Open Market | 10,000 | $727K | 9/10/2025 | View on chart |
| RDNT | ▼ Sell | Open Market | 5,000 | $356K | 8/27/2025 | View on chart |
| RDNT | ▼ Sell | Open Market | 5,536 | $332K | 5/15/2025 | View on chart |
| RDNT | ▼ Sell | Open Market | 2,911 | $175K | 5/15/2025 | View on chart |
| RDNT | ▼ Sell | Open Market | 2,500 | $125K | 3/19/2025 | View on chart |
| RDNT | ▼ Sell | Open Market | 2,500 | $126K | 3/19/2025 | View on chart |
| RDNT | ▼ Sell | Open Market | 5,000 | $241K | 3/18/2025 | View on chart |
| RDNT | ▼ Sell | Open Market | 5,000 | $249K | 3/17/2025 | View on chart |
| RDNT | ▲ Buy | Option Exercise | 11,194 | $112K | 3/5/2025 | View on chart |
| RDNT | ▲ Buy | Option Exercise | 762 | $8K | 3/5/2025 | View on chart |
| RDNT | ▲ Buy | Grant | 27,681 | $0 | 1/8/2025 | View on chart |
| RDNT | ▲ Buy | Option Exercise | 1,380 | — | 1/4/2025 | View on chart |
| RDNT | ▼ Sell | Open Market | 18,597 | $1.2M | 6/12/2024 | View on chart |
| RDNT | ▼ Sell | Open Market | 35,000 | $2.1M | 6/11/2024 | View on chart |
| RDNT | ▼ Sell | Open Market | 15,000 | $917K | 6/10/2024 | View on chart |
| RDNT | ▼ Sell | Open Market | 5,000 | $305K | 6/10/2024 | View on chart |
| RDNT | ▲ Buy | Grant | 17,434 | $0 | 3/1/2024 | View on chart |
| RDNT | ▲ Buy | Option Exercise | 1,380 | — | 1/4/2024 | View on chart |
| RDNT | ▼ Sell | Open Market | 10,000 | $311K | 6/8/2023 | View on chart |
| RDNT | ▼ Sell | Open Market | 15,000 | $464K | 6/7/2023 | View on chart |
| RDNT | ▼ Sell | Open Market | 20,000 | $622K | 6/6/2023 | View on chart |
| RDNT | ▼ Sell | Open Market | 5,000 | $151K | 6/2/2023 | View on chart |
| RDNT | ▼ Sell | Open Market | 5,000 | $150K | 6/2/2023 | View on chart |
| RDNT | ▲ Buy | Option Exercise | 39,127 | $238K | 6/2/2023 | View on chart |
| RDNT | ▲ Buy | Option Exercise | 19,179 | $121K | 6/2/2023 | View on chart |
| RDNT | ▼ Sell | Open Market | 5,000 | $97K | 12/19/2022 | View on chart |
| RDNT | ▼ Sell | Open Market | 10,000 | $205K | 6/1/2022 | View on chart |
| RDNT | ▼ Sell | Open Market | 10,000 | $191K | 5/24/2022 | View on chart |
| RDNT | ▲ Buy | Grant | 20,804 | $0 | 1/4/2022 | View on chart |
| RDNT | ▼ Sell | Open Market | 10,000 | $268K | 12/15/2021 | View on chart |
| RDNT | ▼ Sell | Open Market | 10,000 | $272K | 12/10/2021 | View on chart |
| RDNT | ▼ Sell | Open Market | 10,000 | $277K | 12/6/2021 | View on chart |
| RDNT | ▼ Sell | Open Market | 5,010 | $136K | 12/3/2021 | View on chart |
| RDNT | ▼ Sell | Open Market | 4,990 | $138K | 12/3/2021 | View on chart |
| RDNT | ▲ Buy | Option Exercise | 18,519 | $117K | 11/15/2021 | View on chart |
| RDNT | ▲ Buy | Option Exercise | 16,169 | $162K | 11/15/2021 | View on chart |
| RDNT | ▲ Buy | Option Exercise | 16,772 | $183K | 11/15/2021 | View on chart |
| RDNT | ▼ Sell | Open Market | 17,528 | $496K | 10/1/2021 | View on chart |
| RDNT | ▼ Sell | Open Market | 17,472 | $504K | 10/1/2021 | View on chart |
| RDNT | ▲ Buy | Grant | 2,755 | $0 | 9/21/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 9, 2026
RadNet Q2 Earnings and AI Study News
RadNet received positive marks for its second-quarter testing and diagnostics services earnings. Additionally, a new study suggests DeepHealth AI could help avoid nearly one in five prostate biopsies. These developments provide context for the stock's current position within its 52-week range.
RadNet Q2 Earnings and AI Study News. RadNet received positive marks for its second-quarter testing and diagnostics services earnings. Additionally, a new study suggests DeepHealth AI could help avoid nearly one in five prostate biopsies. These developments provide context for the stock's current position within its 52-week range.